Four-month, four-drug preventive therapy for inactive pulmonary- tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 2, 1999, Pages 508-512

  Goldberg, Stefan V ^a,b   Duchin, Jeffery S ^a   Shields, Tammy ^a   Nolan, Charles M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEADACHE; HUMAN; IMMIGRANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL IMPAIRMENT; VOMITING;

EID: 0032771119     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.2.9808039     Document Type: Article

References (30)

1. 1. American Thoracic Society/Centers for Disease Control. 1990. Diagnostic standards and classification of tuberculosis. Am. Rev. Respir. Dis. 142:725-735.
2. 2. International Union Against Tuberculosis Committee on Prophylaxis. 1982. The efficacy of varying durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT Trial. Bull. WHO 60:555-564.
3. 3. Comstock, G. W., V. T. Livesay, and S. F. Woolpert. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 99:131-138.
4. 4. Ferebee, S. H., and F. W. Mount. 1962. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev. Respir. Dis. 85:490-521.
5. 5. Ferebee, S. H. 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv. Tuberc. Res. 17:28-106.
6. 6. Stead, W. W. 1995. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann. Intern. Med. 122:906-912.
7. 7. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am. Rev. Respir. Dis. 145:36-41.
8. 8. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
9. 9. American Thoracic Society/Centers for Disease Control and Prevention. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
10. 10. American Thoracic Society Committee on Therapy. 1965. Preventive treatment in tuberculosis. Am. Rev. Respir. Dis. 91:297-298.
11. 11. American Thoracic Society/Centers for Disease Control. 1986. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. 134:355-363.
12. 12. Comstock, G. W., C. Baum, and D. E. Snider. 1979. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am. Rev. Respir. Dis. 119:827-830.
13. 13. Snider, D. E., G. J. Caras, and J. P. Koplan. 1986. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. J.A.M.A. 255:1579-1583.
14. 14. Seattle-King County Health Department data on file.
15. 15. Moore, M., I. M. Onorato, E. McCray, and K. G. Castro. 1997. Trends in drug-resistant tuberculosis in the United States, 1993-1996. J.A.M.A. 278:833-837.
16. 16. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. 1989. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 5 years. Am. Rev. Respir. Dis. 139:871-876.
17. 17. Rothman, K. J., and S. Greenland, editors. 1998. Modern Epidemiology, 2nd ed. Lippincott-Raven, Philadelphia. 359-399.
18. 18. Doster, B., F. J. Murray, R. Newman, and S. F. Woolpert. 1973. Ethambutol in the initial treatment of pulmonary tuberculosis: U.S. Public Health Service therapy trials. Am. Rev. Respir. Dis. 107:177-190.
19. 19. Dutt, A. K., D. Moers, and W. W. Stead. 1989. Smear-and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am. Rev. Respir. Dis. 139:867-870.
20. 20. Moore, M., I. M. Onorato, E. McCray, and K. G. Castro. 1997. Trends in drug-resistant tuberculosis in the United States, 1993-1996. J.A.M.A. 278:833-837.
21. 21. Binkin, N. J., P. L. F. Zuber, C. D. Wells, M. A. Tipple, and K. G. Castro. 1996. Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. Clin. Infect. Dis. 23:1226-1232.
22. 22. Zuber, P. L. F., N. J. Binkin, A. C. Ignacio, K. L. Marshall, S. P. Tribble, M. A. Tipple, and R. L. Vogt. 1996. Tuberculosis screening for immigrants and refugees: diagnostic outcomes in the state of Hawaii. Am. J. Respir. Crit. Care Med. 154:151-155.
23. 23. Wells, C. D., P. L. F. Zuber, C. M. Nolan, N. J. Binkin, and S. V. Goldberg. 1997. Tuberculosis prevention among foreign-born persons in Seattle-King County, Washington. Am. J. Respir. Crit. Care Med. 156: 573-577.
24. 24. Fujiwara, P. I., T. R. Frieden, and H. W. Harris. 1997. Clinical Policies and Protocols. Bureau of Tuberculosis Control, New York City Department of Health, 2nd ed.
25. 25. Centers for Disease Control. 1989. A strategic plan for the elimination of tuberculosis in the United States. MMWR 38:1-25.
26. 26. Whalen, C., J. L. Johnson, A. Okwera, D. L. Hom, R. Huebner, P. Mugyenyi, R. D. Mugerwa, and J. J. Ellner. 1997. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the Human Immunodeficiency Virus. N. Engl. J. Med. 337:801-808.
27. 27. Gordin, F., R. Chaisson, J. Matts, C. Miller, C., L. Garcia, R. Hafner, and R. Obrien. 1998. A randomized trial of 2 months of rifampin and pyrazinamide versus 12 months of isoniazid for the prevention of tuberculosis in HIV-positive, PPD positive patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, February 1-5, Chicago, IL.
28. 28. Hasley, N. A., J. S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L. H. Moulton, M. Contave, M. Johnson, H. Davis, L. Geiter, E. Johnson, R. Huebner, R. Boulos, and R. E. Chaisson. 1998. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351:786-792.
29. 29. Centers for Disease Control and Prevention. 1998. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 47(No. RR-20):1-58.
30. 30. Washington State Department of Social and Health Services. Medical Assistance Administration. Resource Based Relative Value Scale (RBRVS): Fee Schedule, Billing Instructions and Policy Guidelines. Olympia, 1998.